Yaakov Naparstek
Corporate Officer/Principal chez The Hebrew University of Jerusalem
Profil
Yaakov Naparstek is the founder of ProtAb Ltd.
(founded in 2005) and Verto Medical Ltd.
(founded in 2003).
At ProtAb Ltd., he held the title of Manager.
At Verto Medical Ltd., he held the title of Chief Scientific Officer from 2003 to 2010.
Currently, he is a Professor at The Hebrew University of Jerusalem.
Previously, he was a Senior Deputy Director General at Hadassah University Hospital and a Director at HBL- Hadasit Bio-Holdings Ltd.
(from 2014 to 2017).
He obtained his undergraduate degree from The Hebrew University Hadassah Medical School.
Postes actifs de Yaakov Naparstek
| Sociétés | Poste | Début |
|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Anciens postes connus de Yaakov Naparstek
| Sociétés | Poste | Fin |
|---|---|---|
| HBL - HADASIT BIO-HOLDINGS LTD | Directeur/Membre du Conseil | 23/03/2017 |
Hadassah University Hospital
 Hadassah University Hospital Hospital/Nursing ManagementHealth Services Hadassah University Hospital engages in the operation of hospitals and medical centers in Israel and abroad. Its services include hospitalization services, medical services, medical tourism, and research and development. The company was founded in 1934 and is headquartered in Jerusalem, Israel. | Corporate Officer/Principal | - |
ProtAb Ltd.
 ProtAb Ltd. Pharmaceuticals: MajorHealth Technology ProtAb Ltd. develops drug treatment for rheumatoid arthritis. It develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune inflammatory diseases. The company was Founded by Yaakov Naparstek in 2005 and is headquartered in Jerusalem, Israel. | Fondateur | - |
Verto Medical Ltd.
 Verto Medical Ltd. BiotechnologyHealth Technology Verto Medical Ltd. (Verto) is focused on the development of a drug-device product, the Lupusorb column, for the treatment of Lupus disease. It is the first of a series of products for the treatment of severe autoimmune diseases. The Lupusorb column is an extra-corporeal immunoadsorbtion column for use during plasmapheresis treatments and utilizes a highly specific proprietary peptide to selectively remove from circulation antibodies associated with the disease. The company is focused on initiating a first-in-man clinical study and is now completing the last product testing studies required prior to the submission of its clinical trial protocol to regulatory authorities. The upcoming clinical study will be carried out in 10 patients and will determine safety and the ability of the Lupusorb column to reduce the circulating levels of antibodies associated with Lupus disease. | Fondateur | - |
Formation de Yaakov Naparstek
| The Hebrew University Hadassah Medical School | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HBL - HADASIT BIO-HOLDINGS LTD | Finance |
| Entreprise privées | 3 |
|---|---|
Verto Medical Ltd.
Verto Medical Ltd. BiotechnologyHealth Technology Verto Medical Ltd. (Verto) is focused on the development of a drug-device product, the Lupusorb column, for the treatment of Lupus disease. It is the first of a series of products for the treatment of severe autoimmune diseases. The Lupusorb column is an extra-corporeal immunoadsorbtion column for use during plasmapheresis treatments and utilizes a highly specific proprietary peptide to selectively remove from circulation antibodies associated with the disease. The company is focused on initiating a first-in-man clinical study and is now completing the last product testing studies required prior to the submission of its clinical trial protocol to regulatory authorities. The upcoming clinical study will be carried out in 10 patients and will determine safety and the ability of the Lupusorb column to reduce the circulating levels of antibodies associated with Lupus disease. | Health Technology |
ProtAb Ltd.
ProtAb Ltd. Pharmaceuticals: MajorHealth Technology ProtAb Ltd. develops drug treatment for rheumatoid arthritis. It develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune inflammatory diseases. The company was Founded by Yaakov Naparstek in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Hadassah University Hospital
Hadassah University Hospital Hospital/Nursing ManagementHealth Services Hadassah University Hospital engages in the operation of hospitals and medical centers in Israel and abroad. Its services include hospitalization services, medical services, medical tourism, and research and development. The company was founded in 1934 and is headquartered in Jerusalem, Israel. | Health Services |
